Information  X 
Enter a valid email address

ABEONA THERAPEU (0H7R)

Date Time Source Announcement
15 Apr 2019 7:41 pm
GNW
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting
04 Apr 2019 1:25 pm
GNW
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
18 Mar 2019 8:45 pm
GNW
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
31 Jan 2019 1:00 pm
GNW
Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
09 Nov 2018 9:20 pm
GNW
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
05 Nov 2018 12:00 pm
GNW
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
18 Oct 2018 1:03 pm
GNW
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
12 Sep 2018 1:45 pm
GNW
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
09 Aug 2018 9:20 pm
GNW
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
11 May 2018 1:15 pm
GNW
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
23 Apr 2018 1:15 pm
GNW
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
20 Apr 2018 1:15 pm
GNW
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
02 Apr 2018 1:15 pm
GNW
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
16 Mar 2018 9:32 pm
GNW
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
07 Feb 2018 1:45 pm
GNW
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
02 Feb 2018 1:45 pm
GNW
Abeona Therapeutics Announces Upcoming Presentations at the 14th Annual WORLDSymposium
29 Jan 2018 1:45 pm
GNW
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
20 Dec 2017 1:45 pm
GNW
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
15 Nov 2017 1:25 pm
GNW
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
13 Nov 2017 1:45 pm
GNW
Abeona Management to Present at Multiple Conferences in November
09 Nov 2017 1:45 pm
GNW
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
04 Oct 2017 1:52 pm
GNW
Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio
16 Aug 2017 2:38 pm
GNW
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t